We showed previously that Lyn is a substrate for caspases, a family of cysteine proteases, involved in the regulation of apoptosis and inflammation. Here, we report that expression of the caspase-cleaved form of Lyn (LynDN), in mice, mediates a chronic inflammatory syndrome resembling human psoriasis. Genetic ablation of TNF receptor 1 in a LynDN background rescues a normal phenotype, indicating that LynDN mice phenotype is TNF-a-dependent. The predominant role of T cells in the disease occurring in LynDN mice was highlighted by the distinct improvement of LynDN mice phenotype in a Rag1-deficient background. Using pan-genomic profiling, we also established that LynDN mice show an increased expression of STAT-3 and inhibitory members of the NFjB pathway. Accordingly, LynDN alters NFjB activity underlying a link between inhibition of NFjB and LynDN mice phenotype. Finally, analysis of Lyn expression in human skin biopsies of psoriatic patients led to the detection of Lyn cleavage product whose expression correlates with the activation of caspase 1. Our data identify a new role for Lyn as a regulator of psoriasis through its cleavage by caspases.
Introduction
The Src family of non-receptor protein tyrosine kinase, includes Src, Lyn, Fyn, Lck, Hck, Fgr, Blk, Yes and Yrk, and has a crucial function in cell-cycle control, adhesion, migration, proliferation, survival and differentiation of multicellular organisms (Thomas and Brugge, 1997) . All Src family members share a common structural organization consisting of an N-terminal unique domain that contains acylation sites required for their localization to the plasma membrane; SH3 and SH2 (src homology) domains followed by a C-terminal catalytic tyrosine-kinase domain, and finally a region that contains conserved regulatory tyrosine phosphorylation sites (Ingley, 2008) . Src kinases are activated by a wide variety of cell-surface receptors. The membrane localization of Src tyrosine kinases seems essential to trigger the intracellular signalling pathways. Indeed, removal of their acylation residues gives a completely non-functional protein in receptor signalling Garber et al, 1985; Kabouridis et al, 1997; Lang et al, 1999) .
The role of Src tyrosine kinase Lyn has been well established in haematopoietic cells (Xu et al, 2005) , but several studies now indicate that Lyn also controls the behaviour of other tissues and cell types (Chen et al, 1996; Stettner et al, 2005; Zhao et al, 2006; Gong et al, 2008) . We have recently identified Lyn as a new substrate for the apoptotic executioner caspases 3 and 7, observed to function as one on activation of B-cell antigen receptor and death receptors of the TNF family in immature B cells (Luciano et al, 2003) . The cleavage of Lyn by caspases occurs in its N-terminal region (after Asp18) and leads to the relocation of the kinase from the plasma membrane to the cytosol. When overexpressed in immature B cells, this caspase-cleaved form, referred to as LynDN, behaves as a cell death inhibitor (Luciano et al, 2003) .
Caspases define a large family of aspartate-specific cysteine-dependent proteases with central functions during apoptosis. However, it is also clearly admitted that besides their well-characterized role in apoptosis, caspases can also have pivotal function in proliferation, differentiation and inflammation (Nadiri et al, 2006; Lamkanfi et al, 2007) . Briefly, caspases are classified into two subfamilies: (i) inflammatory and (ii) apoptotic caspases. Activation of these is linked to the formation of multimeric protein complexes. Thus, during inflammation, the formation of the inflammosome leads to the activation of the inflammatory caspase-1 that is required at least for the processing and subsequent release of active pro-inflammatory cytokines, such as IL-1b and IL-18 (Martinon and Tschopp, 2007) .
To decipher the biological effect of the caspase-cleaved form of Lyn, we generated transgenic mice that expressed this transgene in all tissues. LynDN transgenic mice develop a skin inflammatory syndrome that shows features common in psoriasis (i.e. hyperkeratosis, scaling, inflammatory-cell infiltrates and increased cytokine expression, including TNF-a and IL-23). Backcrossing LynDN mice in a TNF receptor 1-deficient background fully rescues the normal mouse phenotype, indicating its dependence on the pro-inflammatory cytokine TNF-a. Moreover, LynDN phenotype was distinctly improved in a Rag1-deficient background underlying the role of T lymphocytes in the pathogenesis of the disease. We also establish that LynDN increases STAT-3 activation and diminishes NFkB activation, both conditions that have been previously reported to induce a psoriasis-like syndrome in mice (Pasparakis et al, 2002; Sano et al, 2005; Rebholz et al, 2007) . Finally, analysis of Lyn expression in skin biopsies from patients suffering from psoriasis identifies caspase-cleaved form of Lyn whose expression correlates with the activation of inflammatory procaspase 1. Therefore, our data identify LynDN transgenic mice as a new model of psoriasis that could be suitable for pre-clinical studies aimed at understanding and curing this disease.
Results

Characterization of LynDN transgenic mice
To study the biological relevance of the caspase-cleaved form of Lyn, we generated transgenic mice expressing LynDN in all tissues. Four independent founders expressing LynDN were obtained, and all developed the same phenotype. LynDN was highly expressed in heart and muscle, moderately in spleen, thymus, lung and kidney, and to a weaker extent in skin and liver (Supplementary Figure S1A) . LynDN expression and activity was maintained at the same level in transgenic mice, throughout the lifespan of mice (Supplementary Figure S1B and data not shown).
LynDN mice were born in the expected Mendelian ratio and were macroscopically indistinguishable from their control littermates until postnatal day 6 (Supplementary Figure  S3A) . Then, all LynDN transgenic mice developed drastic skin defects characterized by inflexible thickened skin and hyperkeratosis, with major abnormalities around day 15 ( Figure 1A ). LynDN mice could be classified into 2 subgroups based on the severity of their skin phenotype, either mild with small scaly patches affecting ears, tails, paws and the hairy back skin ( Figure 1B and C) , or acute and characterized by skin lesions covering the whole body. The majority of mice showing the acute phenotype (about 50%) died within 2 weeks. Such mice were runted and showed decreased feeding activity but the exact cause of death remained unknown. It should be noted that the severity of the skin phenotype was unrelated to the level of LynDN transgene expression (data not shown). Some LynDN mice also presented with oedema of paws ( Figure 1D ) with alteration of nails, suggesting an inflammatory response of the joints.
Although they consistently presented with growth retardation and loss of weight (Supplementary Figure S2A) , transgenic mice were fertile and their lifespan was roughly similar to that of control mice. To confirm that LynDN mice phenotype was indeed linked to the expression of the caspasecleaved form of Lyn, we generated transgenic mice expressing the caspase non-cleavable form of Lyn (LynD18A). LynD18A progeny failed to develop LynDN phenotype (Supplementary Figure S2B) although transgene expression and relative enzymatic activity of LynDN and LynD18A in skin and different other organs (data not shown) were comparable (Supplementary Figure S2C) .
We showed previously that Fyn, another member of the Src family of tyrosine kinases, is also cleaved by caspases through a similar mechanism . We thus generated transgenic mice expressing the caspase-cleaved form of Fyn (FynDN) in a similar manner as described above for LynDN mice. Three founders were obtained that gave progeny with no apparent phenotype (Supplementary Figure S2B) showing that skin defects in LynDN mice is intrinsic to the expression of the cleaved form of Lyn and not to the expression of any other Src kinase. Analysis of the skin phenotype of LynDN transgenic mice To characterize the skin lesions observed in LynDN mice, we carried out histological and immunofluorescence analysis of skin samples isolated from transgenic and control mice (Figure 2 ). The LynDN mice skin showed marked hyperplasia of the epidermis (acanthosis), loss of granular layer (hypogranulosis), thickened, cornified layer (hyperkeratosis) containing a large number of nuclei, compatible with parakeratosis ( Figure 2A ). The skin from transgenic mice also showed increased Ki67 expression, indicating enhanced keratinocyte proliferation ( Figure 2B ). Analysis of proliferation and differentiation markers showed an enhanced expression of keratin 6 in the entire epidermis and broadening of keratin 14-expressing-keratinocyte layers in the epidermal compartment of LynDN mice, together with a reduced expression of keratin 10 and loricrin ( Figure 2C ). Moreover, integrin-b1 was strongly upregulated in LynDN mice as compared with control mice ( Figure 2C ). It should be noted that such an upregulation of integrin-b1 in the skin of psoriatic patient has been already reported by Conrad et al (2007) . The skin phenotype, detected as early as day 3 after birth, was optimal at 2 weeks and a reversion of the skin phenotype was observed in all surviving mice by week 4 (Supplementary Figure S3) . LynDN expression and activity in skin of transgenic mice remained unaffected through the mice lifespan, indicating that the phenotype reversion was not because of the decreased transgene expression or activity (Supplementary Figure S1B) .
One of the main features of psoriasis is the occurrence of inflammatory cell infiltrates into the epidermis and dermis. The skin sections from LynDN mice showed inflammatory infiltrates into the epidermis and dermis (Figure 2A ). An immunofluorescence analysis confirmed the presence of CD4 þ T cells and an increased number of granulocytes and macrophages in the skin of LynDN transgenic mice ( Figure 2D ). In certain instances, granulocyte foci were detected in the epidermis of transgenic mice ( Figure 2E ). This finding indicates that skin hyperproliferation is accompanied by a haematopoïetic cell infiltration, suggesting that an inflammatory response is probably involved in the LynDN transgenic mice phenotype. Accordingly, analysis of inflammatory cytokine mRNA expression in the skin of 2-week-old mice showed an increase in TNF-a, TNF-b, IL-1b, IL-17, IL-18 and IL-23 levels ( Figure 3A and B) . Furthermore, we identified the upregulation of both the chemotactic proteins, S100A8 and S100A9, known to be involved in psoriasis pathogenesis ( Figure 3B ; Zenz et al, 2005; Chan et al, 2006) . The increased level of pro-inflammatory cytokines was closely related to the severity of LynDN mice phenotype. By contrast, all surviving mice showed normalized levels of pro-inflammatory cytokines (data not shown).
LynDN transgenic mice phenotype is strictly dependent on TNF signalling As TNF-a expression was strikingly increased in LynDN transgenic mice and was largely reported to be involved in skin inflammation, we next investigated whether blocking the TNF signalling can rescue the LynDN mice disease. To this end, we crossed LynDN mice with TNFR1-deficient mice (Pfeffer et al, 1993) . Remarkably, LynDN/TNFR1 À/À mice were exempt of skin disease, with normal skin architecture compared with LynDN/TNFR1 þ /À mice ( Figure 4A and B). Although B50% of LynDN/TNFR1 þ /À mice died before day 15 after birth, all LynDN/TNFR1 À/À reached adulthood (data not shown), indicating that the inflammatory syndrome was the main cause of death in LynDN mice. Accordingly, IL-1b, S100A8 and IL-23 expression returned to control level in LynDN/TNFR1 À/À mice as compared with Figure 4C ). To validate the clinical relevance of LynDN mice as a new model for psoriasis, we treated them with etanercept, a leading agent used for treating patients with psoriasis (Nickoloff and Nestle, 2004) . Etanercept was administered at dose of 50 mg/day to 2-dayold LynDN mice for 5 days. The Figure 4D shows that etanercept treatment leads to a distinct improvement of skin lesions in all injected mice as compared with untreated controls. Next, we addressed the role of T cells in the pathogenesis of the LynDN mice phenotype. To do so, we backcrossed LynDN mice with Rag1-deficient mice (Mombaerts et al, 1992) . Conversely, compared with LynDN/Rag1 þ /À mice, which developed a psoriasis-like syndrome indistinguishable from that of LynDN mice, the skin inflammatory disease was considerably improved in LynDN/Rag1 À/À ( Figure 4E ), clearly indicating that T lymphocytes have a significant function in LynDN mice phenotype.
Comparative analysis of gene expression in the skin of WT and LynDN mice
To gain insights into the molecular mechanism of LynDN effect, we compared the pan-genomic profile of several 5-dayold control and LynDN skin mice before the initiation of the inflammatory syndrome. We decided to carry out the experiment at this time point to identify genes whose regulation is directly linked to the expression of LynDN and not a consequence of the inflammatory process. The expression of more than 300 genes was found to be altered in the skin of LynDN transgenic animals (for the complete list of regulated genes please refer to Materials and methods section). The Supplementary Table S1 recapitulates the most relevant genes in psoriasis-like skin inflammatory syndrome. Our pan-genomic approach confirmed the upregulation of keratin 14 and downregulation of keratin 10 and loricrin, and also revealed modulation of other skin differentiation markers, known to be altered during psoriasis, including upregulation of keratin 16 (Supplementary Table S1 ). Moreover, as mentioned earlier we confirmed the upregulation of many cytokines, such as S100A8, S100A9, TNF-a and IL-1b (Supplementary Table S1 and Figure 3A and B). Interestingly, the pan-genomic approach used herein allowed us to focus on two signalling pathways already reported to be involved in psoriasis pathogenesis in both mouse and human. Indeed, we observed the upregulation of STAT-3 mRNA, but of no other STAT mRNA (Supplementary Table S1 ). This was confirmed at the protein level ( Figure 5A ) in LynDN, but not in LynD18A or FynDN mice ( Figure 5B ). Upregulation of STAT-3 was accompanied with an increase in its tyrosine phosphorylation status and consequently by an increase of its activity. Moreover, another very interesting finding of this pan-genomic analysis was the upregulation of inhibitory molecules of the NFkB signalling pathway, including IkBa, IkBz and Bcl-3 in LynDN mice as compared with WT mice ( Figure 5C ). An increased IkBa expression was also confirmed at the protein level in the skin of LynDN mice ( Figure 5D ).
Etanercept-treated mice S100A9 
The caspase-cleaved form of Lyn inhibits the NFjB signalling pathway
The NFkB signalling pathway has a crucial function in the regulation of the transcriptional responses of inflammation (Gerondakis et al, 2006) , and mice deficient for some members of this signalling pathway developed skin disorder that resembles human psoriatic lesions (Pasparakis et al, 2002; Rebholz et al, 2007) . On the basis of these reports and the results of our pan-genomic approach showing an increased expression of inhibitory regulators of NFkB activity (i.e. IkBa, IkBz and Bcl-3), we investigated whether LynDN might alter the NFkB signalling pathway. Briefly, NFkB is sequestered into the cytoplasm through its interaction with the IkBa repressor. The TNF-a stimulation triggers the activation of a serine/threonine kinase complex composed of IKK1/IKK2/ NEMO, leading to IkBa phosphorylation and its further degradation by the proteasome pathway. Following this NFkB is free to translocate to the nucleus and to induce the transcription of a wide range of genes, more specially involved in the inflammatory response (Hayden and Ghosh, 2008) . To investigate the potential role of NFkB, we carried out experiments in both freshly isolated thymocytes and primary keratinocytes derived from control and LynDN mice, and checked the critical steps of the activation pathway described above. The NFkB activation was analysed in thymocytes from control and LynDN mice on TNF-a or anti-CD3 mAb stimulation. As shown in Figure 6A , TNF-a and anti-CD3 mAb induced binding of NFkB to DNA in freshly isolated thymocytes from control mice, but not in those prepared from LynDN transgenic mice. Importantly, IkBa degradation occurred in thymocytes isolated from control or LynDN mice as well ( Figure 6B ). Decreased binding of NFkB to DNA was also seen in primary keratinocytes isolated from LynDN mice with no modification of IkBa degradation ( Figure 6C and D) . Accordingly, p65/RelA translocation to the nucleus was not altered in keratinocytes expressing LynDN ( Figure 6E ). This is consistent with the increased expression of IkBz and Bcl-3, two members of the IkB family, previously described to directly regulate NFkB activity in the nucleus (Richard et al, 1999; Motoyama et al, 2005) . Similar results were obtained using the Ramos B cell line overexpressing LynDN, previously used to identify Lyn cleavage and function in vitro (Luciano et al, 2003) , or mouse embryonic fibroblasts derived from transgenic mice (Supplementary Figure S4) . Finally, as previously mentioned, caspase cleavage of Lyn leads to the relocation of the kinase from plasma membrane to cytosol (Luciano et al, 2003) . The transfection of LynDN fused to GFP confirmed that LynDN is mainly localized in the cytosol and also showed that leptomycin B, an inhibitor of nuclear export, induced the accumulation of LynDN in the nucleus (Supplementary Figure  S4E) . Thus, LynDN modulates NFkB activity directly or indirectly in the nucleus.
Expression of LynDN in human psoriatic skin biopsies
Transgenic mice expressing the caspase-cleaved form of Lyn developed an inflammatory skin disease that shares many, if not all, features of human psoriasis. Recently, Johansen et al (2007) have shown that caspase 1 activity was increased in lesional psoriatic epidermis. An analysis of caspase 1 expression in whole-cell extracts from biopsies, obtained from nonlesional and lesional psoriatic skin, carried out on six patients confirmed that caspase 1 activity is increased in lesional psoriatic epidermis ( Figure 7A ). Moreover, we also checked for the activation status of the apoptotic executioner caspase 7 recently reported to be activated in a caspase 1-dependent manner during inflammatory conditions (Lamkanfi et al, 2008) . Caspase 7 is indeed activated in lesional skin of three patients suffering from psoriasis ( Figure 7B ), concomitantly with caspase 1 activation (data not shown). Accordingly, it is noteworthy that Lyn is efficiently cleaved by recombinant caspase 7 in vitro ( Figure 7C ). On the basis of these observations, we next investigated Lyn expression and cleavage in both non-lesional and lesional psoriatic skin from the 
Discussion
The data presented herein show that ubiquitous expression of the caspase-cleaved form of the Src tyrosine kinase, Lyn, induces a skin inflammatory syndrome that recapitulates the main, if not all, features of human psoriasis (please refer to Table I 
2006
) and therapies using neutralizing antibody directed against these molecules are in process (Lowes et al, 2007) . As psoriasis is a T cell-mediated autoimmune disease, it was of importance to determine whether lymphocytes were involved in the pathogenesis of the psoriasis-like syndrome occurring in LynDN mice. The predominant role of T cells in the inflammatory skin disease occurring in LynDN mice was highlighted by the distinct improvement of LynDN mice phenotype in a Rag1 À/À -deficient background. Importantly, the persistence of a weak residual disease in LynDN/Rag1 À/À mice probably suggests a nonnegligible role of granulocytes and macrophages in the phenotype of LynDN mice, as it is also the case in K14-IKK2 À/À mice (Stratis et al, 2006) .
In addition, the importance of T cells was further substantiated by the inhibition of NFkB activation by TNF-a and anti-CD3 triggering in thymocytes isolated from LynDN mice. Interestingly, this defect in NFkB activation was detected in thymocytes and keratinocytes isolated from LynDN mice, indicating that both T cells and keratinocytes participated in the mice phenotype.
We have previously shown that on caspase cleavage beyond aspartate 18 Lyn is relocated from the plasma membrane to the cytosol but its SH2/SH3 domains and tyrosine kinase activity remain intact ). Mice deficient for Lyn suffer a deficit of mature B cells (Nishizumi et al, 1995; Chan et al, 1997) and an autoimmune disease (Harder et al, 2001) but no skin defects have been reported in these mice, strongly suggesting that LynDN mice phenotype is not a consequence of a dominant-negative effect of LynDN toward native Lyn signalling. Active form ERK2 Figure 7 Expression of Lyn in human psoriatic skin biopsies. Whole-cell extracts were prepared from biopsies isolated from lesional and nonlesional psoriatic skin and analysed by western blot. SDS-PAGE separated proteins were probed with antibody recognizing procaspase 1 and intermediate form of caspase 1 (A, upper panels) and procaspase 7 and active form (B, upper panel). ERK2 (A and B, lower panels) was used as loading control, (C) Full-length Lyn and LynD18A cDNAs were transcribed and translated in vitro with 35 S-methionine and incubated with purified recombinant caspases 3, 6, and 7 (25 ng) for 15 h at 371C. The reaction products were then analysed using SDS-PAGE and autoradiography. (D) Whole-cell extracts were prepared from biopsies isolated from lesional and non-lesional psoriatic skin and analysed for Lyn expression.
The role of the Src tyrosine kinase Lyn has been well established in haematopoietic cells (Xu et al, 2005) , but several studies also indicate that Lyn controls the behaviour of other tissues and cell types (Chen et al, 1996; Stettner et al, 2005; Zhao et al, 2006; Gong et al, 2008) . The expression of Lyn in mouse keratinocytes has been previously reported (Calautti et al, 1995; Joseloff et al, 2002) . In this line, we analysed Lyn expression in skin sections from control and LynDN transgenic mice (Supplementary Figure S5) . Importantly, Lyn was expressed almost essentially in the basal layer of the epidermis (Supplementary Figure S5A) . In LynDN transgenic mice, Lyn was expressed all along the epidermis (Supplementary Figure S5B) . Interestingly, Lyn was also present in some cells of the dermis in both control and LynDN mice (Supplementary Figure S5A and B) . Moreover, expression of Lyn was confirmed by western blotting in primary mouse keratinocytes (Supplementary Figure S5C) and in primary human keratinocytes (data not shown).
Thus, it seems that the main difference between LynDN and native Lyn is the subcellular localization of the protein.
We hypothesized that once relocated LynDN might have access to new substrates in the cytoplasm and/or the nucleus that could participate in the pathogenesis of the skin disease showed by LynDN transgenic mice. By contrast, mice expressing the caspase-cleaved form of Fyn failed to develop any apparent phenotypic abnormalities, indicating that LynDN and FynDN show distinct intrinsic properties probably linked to the set of substrates they specifically control. Another point of particular interest of this study comes from the observation that transgenic mice overexpressing an uncleavable form of Lyn, in which aspartate 18 has been mutated to an alanine, failed to develop the skin inflammatory syndrome observed in LynDN mice. This mouse model reinforces the idea that the localization, rather than the amount of Lyn, is critical for the establishment of LynDN transgenic mice phenotype. These findings are in agreement with several lines of evidence suggesting that the subcellular localization of different Src kinase members is at least as important as the regulation of their kinase activity Kabouridis et al, 1997; Lang et al, 1999; Ricci et al, 2001; Luciano et al, 2003) . Thus, conversely to native membraneanchored Lyn, the relocated caspase-cleaved form of Lyn most probably controls specific targets involved in inflammatory responses.
A histological analysis of the heart and muscle, tissues in which LynDN expression is the highest, failed to reveal any defects. By contrast, the skin, in which transgene expression is modest, showed major hallmarks of inflammation. However, although expression level and relative kinase activity of LynDN are constant throughout the mouse lifespan, spontaneous inflammatory syndrome showed by LynDN mice, those survive, is improved by week 5. The disappearance of inflammatory skin disease has already been reported for transgenic mice expressing constitutive active STAT-3 specifically in epidermis (Sano et al, 2005) and reversion of skin lesion is one of the remarkable features of psoriasis (Nickoloff et al, 2007) . Importantly, STAT-3 transgenic mice developed a spontaneous psoriasis-like disorder very early after birth, whereas in aged mice psoriasis this was observed only on wounding. Interestingly, a comparative pan-genomic analysis of control and LynDN mice skin revealed a specific upregulation of STAT-3 with no modification of expression of any other STAT proteins. Moreover, STAT-3 was constitutively activated in the skin of LynDN mice, strongly suggesting a relationship between STAT-3 and LynDN expression. Taking into account the fact that tyrosine phosphorylation of STAT transcription factor by Src kinase, such as Lyn has been recently described (Wang et al, 2007) , it is tempting to speculate that transcriptional regulation and activation of STAT-3 by LynDN may be responsible for the transgenic mice phenotype.
As previously specified, the skin disease of LynDN mice also shares some features with the one occurring in IKK2 À/À , NEMO À/À or IkBa À/À mice (Pasparakis et al, 2002; Nenci et al, 2006; Rebholz et al, 2007) , characterized by an early onset of hyperkeratosis and immune cell infiltration after birth. These observations, together with the fact that skin of LynDN mice expressed high level of IL-1b and TNF-a prompted us to investigate the potential role of NFkB signalling pathway in LynDN phenotype. We found a marked decrease in NFkB binding activity, in both freshly isolated thymocytes and primary keratinocytes, without significant alteration of the upstream NFkB activation pathway on TNF-a stimulation. Moreover, a net decrease in the transactivation of kB-Luciferase reporter gene expression was detected in Ramos B cells overexpressing LynDN (Supplementary Figure S5D ). Therefore, alteration of NFkB activation by LynDN probably occurs at the level of target gene regulation in agreement with the observed localization of LynDN in the nucleus. Interestingly, Greten et al (2007) recently showed that NFkB is a negative regulator of IL-1b secretion. Thus, the increased expression of IL-1b observed in LynDN mice is consistent with the potential inhibition of NFkB signalling pathway by LynDN. Attempts to detect a direct interaction between p65 and p50 NFkB subunits and LynDN were unsuccessful. This, however, does not rule out the possibility of an indirect effect of LynDN on these NFkB subunits. Another point of particular interest of this study is the transcriptional regulation by LynDN of several known inhibitors of the NFkB pathway, including increased expression of IkBa, Ikbz and Bcl-3. Among them the latter two are known to be localized in the nucleus (Zhang et al, 1994; Motoyama et al, 2005) . The exact mechanism by which LynDN alters the NFkB pathway warrants a detailed further study. Nevertheless, we could imagine a model in which LynDNmediated inhibition of NFkB activation is mediated through transcriptional induction of Bcl-3 by STAT-3 (Brocke-Heidrich et al, 2006 ). In such model, LynDN would activate STAT-3, which in turn would increase Bcl-3 expression, leading to the inhibition of NFkB activation. This model is in line with the observation that transgenic mice expressing constitutively activated STAT-3 in the epidermis develop a psoriasis-like syndrome and show an increased IkBa expression (Sano et al, 2005) .
Psoriasis is a T cell-mediated autoimmune disease of unknown etiology, which is characterized by acanthosis, parakeratosis (i.e the presence of nuclei in the corneum substratum) and immune cell infiltration (Lowes et al, 2007) . Accordingly, the psoriasis-like disease showed by LynDN mice was improved distinctly in LynDN/Rag1 À/À mice. As LynDN mice recapitulate the main features of human psoriasis (Table I) , we sought to analyse whether Lyn expression and cleavage were modulated in human psoriatic skin lesions. An analysis of Lyn expression in human psoriatic skin biopsies showed the presence of a cleaved form of Lyn, which correlates with caspase 1 and caspase 7 activation. The cleavage of caspase 1 has been already reported in human psoriasis biopsies (Johansen et al, 2007) , but to our knowledge this is the first description of caspase 7 activation in this disease. Accordingly, Lamkanfi et al (2008) very recently established that apoptotic executioner caspase 7 is activated directly by caspase 1 during an inflammatory process, reinforcing the concept of a crosstalk between these two classes of caspases. In addition, Lyn cleavage was not detected in non-lesional skin biopsies, in which caspases 1 and 7 activation was absent, strongly suggesting a causal link between these two events. It should be noted that Ayli et al (2008) recently found an activation of Src tyrosine kinases in hyperproliferative epidermal disorders, including psoriasis. In this study Src kinase activity was associated with both membrane and cytoplasmic localization.
In summary, we report a new and original mechanism by which the caspase-cleaved form of Lyn triggered a psoriasislike syndrome in mice. Many animal models for psoriasis have been developed (Gudjonsson et al, 2007; Schon, 2008) . However, although it is important to consider that none of these animal models shows all the features of human psoriasis, each of them has proven to be useful for the better understanding of the pathogenesis of this disease. Nevertheless, the LynDN transgenic mice phenotype described herein, which recapitulates the main characteristics of human psoriasis (Table I) can be improved by etanercept ( Figure 4D ). As such, it may be particularly valuable as an animal model to validate new therapeutic drugs against psoriasis.
Materials and methods
Generation of transgenic mice
To drive an ubiquitous expression of the caspase-cleaved form of Lyn (LynDN), its uncleavable form (LynD18A) or the caspasecleaved form of Fyn (FynDN), we used the pCAGGS vector (a generous gift from H. Niwa), in which the cytomegalovirus (CMV) enhancer and the chicken b-actin promoter are located upstream of the MCS region. In addition, a rabbit b-globin polyadenylic acid sequence is located downstream of the MCS region (Niwa et al, 1991) .
LynDN, LynD18A and FynDN were PCR amplified from the corresponding pcDNA3 plasmids (Ricci et al, 1999; Luciano et al, 2001) Transgenic founders were crossed with C57BL/6 (Janvier) mice to generate lines. F1 transgenic progeny were crossed with C57BL/6 mice to maintain lines. The phenotype of LynDN mice described was maintained through at least 10 generations and showed total penetrance.
The expression of LynDN and LynD18A proteins was confirmed by western blot analysis of various tissues with anti-Lyn antibody. In some experiments, LynDN mice were backcrossed with TNFR1-or Rag1-deficient mice (Jackson Laboratory).
For genotyping, DNA was isolated from tail snips and subjected to PCR with the following primers for pCAGGS-LynDN or pCAGGSLynD18A: sense 5 0 -CCTTCTTCTTTTTCCTACAGC-3 0 and antisense 5 0 -GCTCCTGCACTGTTCCCTGG-3 0 ; for pCAGGS-FynDN: sense 5 0 -CC TTCTTCTTTTTCCTACAGC-3 0 and antisense 5 0 -CGGGCTTCCCA CCAATCTC-3 0 ; for TNFR1 and Rag1 deficient mice the genotyping protocol is available at the Jackson laboratory website.
The animal studies were approved by the Institutional Animal Care and Use Committee of the Centre Méditerranéen de Médecine Moléculaire (INSERM U895).
Primary mouse keratinocyte culture and thymocyte isolation Primary keratinocyte were isolated from adult mice (Romero et al, 1999) . Control and LynDN mice (6-12 weeks) were killed, shaved and washed with 70% ethanol. The skin was removed, rinsed in 70% ethanol and in PBS containing 250 mg/ml penicillin/streptomycin, and all the subcutaneous tissue was scraped off. The skin was then incubated in 0.25% trypsin overnight at 41C. The epidermis separated from the dermis was minced and placed in keratinocyte medium (William's E medium containing 2 mM glutamine, 10% chelated FCS, 5 mg/ml insulin, 10 mM cholera toxin, 2 mM triiodothyronine, 10 ng/ml epidermal growth factor, 0,4 mg/ml hydrocotisone and 18 mM adenine). Cell suspension was filtered through a 70 mm Teflon mesh, centrifuged and resuspended in complete keratinocyte medium. Cells were then seeded onto collagen I-coated dishes (25 mg/ml) in the presence of a feeder layer of lethally irradiated fibroblasts. Cells were incubated at 321C under 8% CO 2 and the medium was changed thrice a week.
For the preparation of cells from the thymus, the organ was removed from individual mouse and passed through a nylon membrane (70 mM porosity) to obtain single-cell suspensions in RPMI 1640 medium (with 10% FCS, 50 mM b-mercaptoethanol, 100 mg/ml penicillin/streptomycin, 2 mM glutamine).
Immunoblotting
Mouse tissues homogenized with a polytron or cells were lysed in buffer containing 50 mM Tris (pH 7.5), 100 mM NaCl, 5 mM EDTA, 10 mM NaF, 10 mM Na 3 VO 4 , 1 mM PMSF, 1 mM leupeptin, 20 mg/ml aprotinin and 1% Triton X-100. Proteins were separated using SDS-PAGE and transferred onto PVDF membrane (Immobilon-P, Millipore). After blocking nonspecific binding sites, the membranes were incubated with specific antibodies. The membranes were washed and incubated further with horseradish peroxidaseconjugated antibody. Immunoblots were revealed by autoradiography using the enhanced chemiluminescence detection kit (Pierce).
RT-PCR and Real time quantitative-PCR analysis
Tissues were harvested and incubated in RNAlater (Ambion) before RNA extraction. Total RNA was isolated using Trizol Reagent (Invitrogen) after tissues homogenization with polytron. The supernatant was cleared by centrifugation, precipitated with isopropanol and resuspended in RNAse and DNAse-free water.
For RT-PCR, total RNA (2 mg) was reverse transcribed using the SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer's instructions in a 40 ml final volume. cDNAs (2 ml) were amplified using 1 U of Taq polymerase (New England Biolabs, Ipswich, MA, USA) in a final volume of 25 ml buffer containing 1.5 mM MgCl 2 , 0.2 mM deoxynucleoside triphosphate (dNTP) and 0.5 mM of the primers (for primer sequences, please referred to Supplementary data).
For RQ-PCR analysis, 1 mg of RNA, previously treated with DNAse1, was reverse transcribed using random priming and MultiScribe reverse transcriptase (Applied Biosystems). RT-PCR was carried out in an ABI PRISM 5700 Sequence Detector System (Applied Biosystems) using the SYBR Green detection protocol as outlined by the manufacturer. Gene-specific primers were designed using the Primer Express software (Applied Biosystems). The relative expression level for target genes was normalized for RNA concentrations with four different housekeeping genes (GAPDH, b-actin, HPRT and ubiquitin). The mRNA values are expressed as arbitrary units and represent the mean±s.d. of duplicates and are representative of three independent experiments.
Preparation and immunostaining of tissue
The tissues were collected from mouse and were either preserved in Formol for histological analysis (haematoxylin/eosin staining) or were frozen at À801C for subsequent immunostaining experiments. The tissue sections (6 mm) were fixed in ice-cold acetone (10 min at À201C) and blocked in 2% BSA/PBS for 1 h. Then, tissue sections were incubated with the appropriate specific primary antibody for 1 h at room temperature. After three washes with PBS, tissue sections were incubated with the appropriate fluorescentconjugated secondary antibody or streptavidin conjugates. The preparations were mounted in fluoromount (Southern Biotech) and images were acquired using Leica microscope and LAF6000 software.
Human psoriatic skin biopsies A total of five paired non-lesional and lesional psoriatic skin biopsies were obtained from Archet Hospital of Nice (Dermatology department; Head of Department Pr Ortonne) with the consent of the patients, according to France regulation. In addition, whole-cell protein extracts from four paired non-lesional and lesional psoriatic skin biopsies were obtained from Dr Iversen (Denmark). The local ethical committee of Aarhus, Denmark approved all studies and informed consent was obtained from each patient.
Microarray experiments
Total RNA was extracted using the RNeasy kit Mini (Qiagen). The RNA was quantified using nanodrop spectrophotometry. RNA quality was evaluated using the Agilent Bioanalyzer 2100 and Lab-on-Chip Nano 6000 chip (ratio of the 28S:18S RNAX1.5).
Pan-genomic microarrays were printed using mouse RNG/MRC oligonucleotide collection as previously described by Le Brigand et al (2006) . The list containing 25 011 probes spotted on the microarray is available at http://www.microarray.fr (follow the link to 'mouse national set'). The RNA was labelled and hybridized as described by Moreilhon et al (2005) . We compared in pairs three LynDN and three control mice, and for each comparison Cyanine dyes were inverted to reduce the impact of dye bias. The experimental data and associated microarray designs have been deposited in the NCBI gene expression omnibus (GEO; http:// www.ncbi.nlm.nih.gov/geo/) under series GSE12722 and platform record GPL1476.
Statistical analysis
The data were normalized using the print tip Lowess method (within-array normalization method) and by quantile (betweenarray normalization method) using the Limma package in the software package R Bioconductor (Wettenhall and Smyth, 2004) . Differentially expressed genes were selected using a BenjaminiHochberg correction of the P-value for multiple tests, based on a P-value o0.05. All normalized data sets were registered in the GEO database under the accession number GSE12722.
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
